跳转至内容
Merck
CN

SML1026

Lasofoxifene tartrate

≥98% (HPLC)

别名:

(-)-cis-6-Phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol tartrate, (5R,6S)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol tartrate, CP-336,156 tartrate

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C28H31NO2 · C4H6O6
化学文摘社编号:
190791-29-8
分子量:
563.64
UNSPSC Code:
51111800
PubChem Substance ID:
329825634
NACRES:
NA.77

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

SMILES string

OC1=CC=C(C(CC[C@@H]2C3=CC=CC=C3)=C1)[C@H]2C4=CC=C(OCCN5CCCC5)C=C4.O=C(O)[C@@H](O)[C@H](O)C(O)=O

InChI

1S/C28H31NO2.C4H6O6/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29;5-1(3(7)8)2(6)4(9)10/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2;1-2,5-6H,(H,7,8)(H,9,10)/t26-,28+;1-,2-/m10/s1

InChI key

INEHJXCWEVNEDZ-LUDNRVPPSA-N

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 10 mg/mL, clear

storage temp.

2-8°C

Quality Level

100

Biochem/physiol Actions

Lasofoxifene is a third-generation selective estrogen receptor modulator (SERM).
Lasofoxifene is a selective estrogen receptor modulator (SERM).
Lasofoxifene possesses strong resistance to intestinal wall glucuronidation and thus promotes oral bioavailability. In postmenopausal women, it reduces bone resorption, bone loss and low density lipoprotein (LDL) cholesterol. Selective and regular dose of Lasofoxifene is known to reduce the risk of fractures, breast cancer, major coronary heart disease, and stroke.

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000463040
0000463040
0000237043
0000237043
0000197232

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis.
Gennari L, et al.
Expert Opinion on Investigational Drugs, 15(9), 1091-1103 (2006)
Lasofoxifene in postmenopausal women with osteoporosis.
Cummings S R, et al.
The New England Journal of Medicine, 362(8), 686-696 (2010)
Nam Sook Kim et al.
Journal of separation science, 43(14), 2750-2765 (2020-04-17)
An analytical method for the simultaneous and reliable determination of 20 antigout and antiosteoporosis pharmaceutical compounds in adulterated health food products was developed using liquid chromatography with electrospray ionization tandem mass spectrometry and liquid chromatography with quadrupole-time-of-flight mass spectrometry. The
Nam Sook Kim et al.
Journal of pharmaceutical and biomedical analysis, 179, 113003-113003 (2019-12-10)
The aim of this study was to simultaneously determine the presence of unauthorized drug substances in health foods and herbal products used in the treatment of conditions such as gout and anti-osteoporosis. Therefore, we developed and optimised a rapid and
Kaitlyn J Andreano et al.
Breast cancer research and treatment, 180(3), 635-646 (2020-03-05)
The combination of targeting the CDK4/6 and estrogen receptor (ER) signaling pathways with palbociclib and fulvestrant is a proven therapeutic strategy for the treatment of ER-positive breast cancer. However, the poor physicochemical properties of fulvestrant require monthly intramuscular injections to

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持